2020
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
Abraham NS, Yang EH, Noseworthy PA, Inselman J, Yao X, Herrin J, Sangaralingham LR, Ngufor C, Shah ND. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Alimentary Pharmacology & Therapeutics 2020, 52: 646-654. PMID: 32657466, PMCID: PMC8183594, DOI: 10.1111/apt.15790.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedClopidogrelCohort StudiesFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative ComplicationsPrasugrel HydrochlorideRetrospective StudiesThromboembolismTicagrelorTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionAcute coronary syndromeGIB ratesGIB riskCoronary syndromeGastrointestinal bleedingSTEMI patientsCoronary interventionHazard ratioMajor adverse cardiac eventsRisk reductionCox proportional hazards modelNSTE-ACS patientsAdverse cardiac eventsMajor bleeding eventsConfidence intervalsInverse probability treatmentProportional hazards modelMedicare Advantage enrolleesBleeding eventsClopidogrel prescriptionGIB eventsNSTE-ACSGastrointestinal bleedBaseline characteristics
2019
Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age
Abraham NS, Noseworthy PA, Inselman J, Herrin J, Yao X, Sangaralingham LR, Cornish G, Ngufor C, Shah ND. Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age. Clinical Gastroenterology And Hepatology 2019, 18: 337-346.e19. PMID: 31108228, PMCID: PMC7386161, DOI: 10.1016/j.cgh.2019.05.017.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationFibrinolytic AgentsGastrointestinal HemorrhageHumansMedicarePlatelet Aggregation InhibitorsRetrospective StudiesRisk FactorsUnited StatesConceptsGastrointestinal bleedingAntiplatelet monotherapyGIB riskAntiplatelet agentsRisk of GIBCombination antithrombotic therapyDifferent antithrombotic regimensDifferent antithrombotic strategiesDrug exposure categoriesProportion of patientsNationwide claims dataMedicare Advantage enrolleesAntithrombotic regimensBleeding increasesAntithrombotic therapyAntithrombotic strategiesElderly patientsCombination regimensPatient ageCombination therapyPrimary diagnosisAntithrombotic drugsAntithrombotic agentsCardiovascular conditionsRetrospective analysis